Therefore, the immune checkpoint inhibitors ipilimumab and nivolumab have a dual mode of action, directly targeting tumor cells expressing CTLA-4, PD-1, and PD-L1, and also by inhibiting the Treg response to tumors. This evidence concerns the gene CTLA4 and neoplasm.